- Home
- TNXP vs RDZN Comparison
TNXP vs RDZN Comparison
Compare TNXP & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TNXP | RDZN |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 87.7M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNXP | RDZN |
|---|---|---|
| Price | $5.24 | $1.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $39.00 | $5.00 |
| AVG Volume (30 Days) | ★ 1.0M | 265.9K |
| Earning Date | 11-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | 72.12 |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $55,021,792.00 |
| Revenue This Year | $325.44 | $41.04 |
| Revenue Next Year | $99.29 | $78.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | 24.21 |
| 52 Week Low | $4.96 | $0.98 |
| 52 Week High | $20.56 | $2.56 |
Technical Indicators
Market Signals| Indicator | TNXP | RDZN |
|---|---|---|
| Relative Strength Index (RSI) | 21.32 | 43.79 |
| Support Level | N/A | $1.09 |
| Resistance Level | $13.73 | $1.44 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 16.18 | 63.48 |
Price Performance
Historical ComparisonAbout TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.